Kymera Therapeutics Company Insiders
KYMR Stock | USD 32.54 0.67 2.02% |
Kymera Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Kymera Therapeutics suggests that virtually all insiders are panicking. Kymera Therapeutics employs about 188 people. The company is managed by 15 executives with a total tenure of roughly 439 years, averaging almost 29.0 years of service per executive, having 12.53 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2025-03-03 | Jeremy G Chadwick | Disposed 1383 @ 30.45 | View | ||
2025-01-06 | Ellen Chiniara | Disposed 3129 @ 41.75 | View | ||
2024-09-17 | Pamela Esposito | Disposed 13500 @ 48.28 | View | ||
2024-08-26 | Jeffrey W. Albers | Disposed 5000 @ 49.1 | View | ||
2024-07-16 | Jared Gollob | Disposed 23145 @ 45.81 | View | ||
2024-07-09 | Bruce Booth | Disposed 453960 @ 38.21 | View | ||
2024-06-12 | Bruce Booth | Disposed 16740 @ 35.45 | View | ||
2024-06-07 | Joanna Horobin | Disposed 8500 @ 32.99 | View |
Monitoring Kymera Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Kymera |
Kymera Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Kymera Therapeutics' future performance. Based on our forecasts, it is anticipated that Kymera will maintain a workforce of slightly above 190 employees by April 2025.Kymera Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2065) % which means that it has lost $0.2065 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3638) %, meaning that it created substantial loss on money invested by shareholders. Kymera Therapeutics' management efficiency ratios could be used to measure how well Kymera Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/23/2025, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.3. At this time, Kymera Therapeutics' Net Tangible Assets are relatively stable compared to the past year. As of 03/23/2025, Non Current Assets Total is likely to grow to about 491.2 M, while Total Current Assets are likely to drop slightly above 389.7 M.As of 03/23/2025, Common Stock Shares Outstanding is likely to drop to about 49.9 M. In addition to that, Net Loss is likely to grow to about (132.4 M)
Kymera Therapeutics Workforce Comparison
Kymera Therapeutics is rated fourth overall in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,477. Kymera Therapeutics holds roughly 188 in number of employees claiming about 8% of equities under Health Care industry.
Kymera Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kymera Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kymera Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Kymera Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 1.2 | 12 | 10 | 732,500 | 29,528 |
2024-12-01 | 0.5 | 1 | 2 | 2,500 | 5,000 |
2024-09-01 | 0.5 | 11 | 22 | 3,029,321 | 588,933 |
2024-06-01 | 1.0 | 12 | 12 | 191,913 | 85,928 |
2024-03-01 | 0.3455 | 19 | 55 | 2,247,185 | 976,904 |
2023-12-01 | 4.0 | 8 | 2 | 434,105 | 20,000 |
2023-09-01 | 1.0 | 1 | 1 | 12,000 | 12,000 |
2023-03-01 | 0.9286 | 13 | 14 | 1,124,902 | 256,330 |
2022-12-01 | 0.1132 | 6 | 53 | 113,732 | 1,871,656 |
2022-06-01 | 3.2857 | 23 | 7 | 325,545 | 109,792 |
2022-03-01 | 0.8182 | 18 | 22 | 932,076 | 297,600 |
2021-12-01 | 0.3077 | 8 | 26 | 115,603 | 231,096 |
2021-09-01 | 0.4 | 14 | 35 | 741,945 | 897,824 |
2021-06-01 | 0.75 | 30 | 40 | 502,026 | 1,461,619 |
2021-03-01 | 0.48 | 12 | 25 | 786,046 | 1,687,051 |
2020-09-01 | 0.65 | 26 | 40 | 25,305,469 | 44,711,628 |
Kymera Therapeutics Notable Stakeholders
A Kymera Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kymera Therapeutics often face trade-offs trying to please all of them. Kymera Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kymera Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Dr DPHIL | CoFounder Chairman | Profile | |
Jared MD | Chief Officer | Profile | |
DPhil DPHIL | CoFounder Chairman | Profile | |
Justine Koenigsberg | Vice Relations | Profile | |
JD Esq | Chief Secretary | Profile | |
Karen Weisbach | Head Culture | Profile | |
Juliet BA | Head Research | Profile | |
Melissa Brody | VP Devel | Profile | |
Elaine Caughey | Chief Officer | Profile | |
Bruce CFA | Chief Officer | Profile | |
Kevin Dushney | VP Operations | Profile | |
Vijay Sabesan | VP Operations | Profile | |
Michael Todisco | VP Fin | Profile | |
Nello MD | President, CoFounder | Profile | |
Jeremy Chadwick | Chief Officer | Profile |
About Kymera Therapeutics Management Performance
The success or failure of an entity such as Kymera Therapeutics often depends on how effective the management is. Kymera Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kymera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kymera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.23) | (0.24) | |
Return On Capital Employed | (0.29) | (0.30) | |
Return On Assets | (0.23) | (0.24) | |
Return On Equity | (0.27) | (0.25) |
Kymera Therapeutics Workforce Analysis
Traditionally, organizations such as Kymera Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kymera Therapeutics within its industry.Kymera Therapeutics Manpower Efficiency
Return on Kymera Therapeutics Manpower
Revenue Per Employee | 250.4K | |
Revenue Per Executive | 3.1M | |
Net Loss Per Employee | 1.2M | |
Net Loss Per Executive | 14.9M | |
Working Capital Per Employee | 2.4M | |
Working Capital Per Executive | 29.5M |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.